United States · 
What does Windham Capital Partners invest in?
Windham Capital Partners invests most often at Series B and Series A (67% of the rounds on record), in sectors such as Venture Capital & Private Equity.
Windham Capital Partners highlights
- 01
15 rounds on record
- 02
Mostly Series B and Series A: 67% of its rounds
- 03
Sole investor in 1 rounds, median $2.5M
What they do
Filed 1 private fund offering with the SEC, the most recent in 2023-11From their own website
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- Venture Capital & Private Equity
- Based in
- New York, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first15 appearances
- 2024
1 round
- Jul
- 2019
2 rounds
- Jun
- Jun
- 2015
5 rounds
- Oct
- Jun
- Jun
- May
- May
- 2014
3 rounds
- Oct
- Apr
- Jan
- 2012
1 round
- Dec
- 2011
2 rounds
- Aug
- Mar
- 2010
1 round
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration2 named
AEAdam E FineManaging Member of General PartneriFiling they signed
JIJoseph I ProtoMemberiForm ADV
We also hold 17 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$94Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Windham Capital Partners LLC
- SEC number
- CRD 299860
What they claim to have backed
From their own portfolio page (on their website)
24 of 37 we have independently watched raise
AltoneuroscienceAndrosCartivaChromacodeControlradCoravinCureatrDelfidiagnosticsEarlensGlysensNebulaNeotractNeusperaNuvairaPersonalgenomeRevelleaestheticsScienceexchangeSubjectwellTailormedUpwardhealthValerahealthVytronusWelldocfore.bioAlconAytubioBlueprinthealthClevercarehealthplanDotscorpLocemiaMc10incNovocureOnewillowPainteqRxwareStrykerVergentbio
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.